Christopher H. van Dyck (born 25 August 1955), is the Founder and Director of the Alzheimer’s Disease Research Unit (ADRU) at Yale University School of Medicine, where he is Professor of Psychiatry, Neurology and Neuroscience. His research uses brain imaging to learn about the progression of pathology in Alzheimer's disease, and to test potential new treatments for this disease.

van Dyck was born in Wichita, Kansas to Barbara Kroll Dyck, an elementary school teacher, and Walter Dyck, a college art professor. He has two brothers, Peter and Tim van Dyck. His family moved to Vermont in 1957, where he grew up in Johnson and Underhill.[1] He graduated from Burlington High School, where he and his partner won the varsity state debate championship.[2]

Alzheimer’s disease research

van Dyck created the Yale Alzheimer’s Research Unit in 1992, performing research on Alzheimer’s disease and related cognitive disorders. He has helped to pioneer the use of SPECT and PET imaging to learn about brain alterations related to cognitive and behavioral changes in Alzheimer’s Disease and the aging brain, and to test potential treatments for Alzheimer’s Disease.

Using SPECT imaging of the Dopamine transporter, van Dyck’s work has shown that there is loss of dopamine from the aging striatum,[3] and that this is related to a slowing of reaction time,[4] a measure of mental chronometry.

van Dyck uses PET imaging to track Alzheimer’s-related pathology, to learn how pathology relates to ApoE genotype, and whether it is diminished by potential treatments. Dr. van Dyck has collaborated with Dr. Richard Carson at the Yale PET Center to test the new PET ligand 11C-UCB-J, which binds to SV2A to provide an assay of presynaptic axon terminals in the human brain. Studies of this ligand in early Alzheimer’s Disease patients have shown a loss of synapses from the perforant path, the connections between the entorhinal cortex and hippocampal formation needed for memory consolidation.[5]

van Dyck and the Yale ADRU have tested potential Alzheimer’s therapeutics for over 20 years. They have contributed to the successful development of memantine now in use for the treatment of mid-late stage Alzheimer’s Disease,[6] and assess potential new therapeutic strategies, e.g. antibodies that reduce amyloid pathology such as Crenezumab,[7] and based on the work of Dr. Stephen Strittmatter, an inhibitor of fyn.[8] van Dyck is the lead author on the New England Journal of Medicine report on lecanemab, the first treatment to significantly slow the course of Alzheimer's disease.[9]

Dr. van Dyck serves on the Steering Committees of the National Institute on Aging Alzheimer's Disease Cooperative Study (ADCS) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). He serves as co-director of the Yale Alzheimer's Disease Research Center with Dr. Strittmatter, and is Director of the Division of Aging and Geriatric Psychiatry at Yale. Dr. van Dyck is the Chair of the Medical and Scientific Advisory Council of the Connecticut chapter of the Alzheimer’s Association. He received the "Compassion and Cure" Award from the Alzheimer's Association in 2005.

Chess

Chris was an avid Correspondence Chess player. In 1992, Chris won the International Correspondence Chess Federation title International Correspondence Chess Master, winning the 1979 Absolute.[10] His games from this tournament have been published, including in Alex Dunne’s Modern Postal Masterpieces.[11]

References

  1. ↑ "Barbara Goss 1926 2016". United States Obituary Notices. 2019-03-05. Retrieved 2020-12-24.
  2. ↑ "BHS Debaters Tops at Tourney". Burlington Free Press. 1973-03-13. p. 7. Retrieved 2020-12-24.
  3. ↑ van Dyck, C; et al. (1995). "Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT". J. Nucl. Med. 36 (7): 1175–81. PMID 7790941.
  4. ↑ van Dyck, C; et al. (2008). "Striatal dopamine transporters correlate with simple reaction time in elderly subjects". Neurobiol Aging. 29 (8): 1237–46. doi:10.1016/j.neurobiolaging.2007.02.012. PMC 3523216. PMID 17363113.
  5. ↑ Chen, MK; et al. (2018). "Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging". JAMA Neurology. July 16 epub ahead of print.
  6. ↑ van Dyck, C; et al. (2007). "A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease". Alzheimer Dis Assoc Disord. 21 (2): 136–43. doi:10.1097/WAD.0b013e318065c495. PMID 17545739. S2CID 25621202.
  7. ↑ Cummings, J; et al. (2018). "A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease- The ABBY study". Neurology. 90 (21): e1889–97. doi:10.1212/wnl.0000000000005550. PMC 5962917. PMID 29695589.
  8. ↑ Nygaard, HB; et al. (2015). "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease". Alzheimers Res Ther. 7 (1): 35. doi:10.1186/s13195-015-0119-0. PMC 4396171. PMID 25874001.
  9. ↑ van Dyck et al., N Engl J Med 388: 9-21, 2023
  10. ↑ Alex Dunne (2012). The Absolute Correspondence Championship of the United States Chess Federation, 1976-2010. McFarland. pp. 348pp.
  11. ↑ Alex Dunne (1994). Modern Postal Masterpieces. Thinkers' Press. pp. 141pp.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.